OncoMatch/Clinical Trials/NCT07353671
Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis
Is NCT07353671 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Topical application of Periplaneta americana-derived Meilian Fuxin Solution for radiation-induced dermatitis.
Treatment: Topical application of Periplaneta americana-derived Meilian Fuxin Solution — To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify